反应详情

The title compound is prepared analogously as described for example 11 using 4-[(4aR,10bR)-9-ethoxy-8-methoxy-3,4,4a,10b-tetrahydro-1H-thiopyrano[4,3-c]isoquinolin-6-yl]benzoic acid (159 mg; compound C10), 1-[(2-ethyl-1,3-oxazol-4-yl)methyl]-6-phenyl-3-(piperidin-4-yl)thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride (190 mg; compound B41), HBTU (167 mg), DIPEA (207 mg) and DCM (8 ml). After 3 h additional HBTU (91 mg) and 4-[(4aR,10bR)-9-ethoxy-8-methoxy-3,4,4a,10b-tetrahydro-1H-thiopyrano[4,3-c]isoquinolin-6-yl]benzoic acid (20 mg; compound C10) are added and the mixture is stirred for 22 h at RT. Saturated aqueous sodium bicarbonate solution (2.5 ml) is added and the mixture is extracted twice with DCM (2×5 ml). The combined organic layers are applied to a phase separator and the solvent is removed under vacuo. The resulting residue is purified by flash column chromatography for three times [amino phase silica gel, eluation gradient: cyclohexane/EtOAc, 100/0 to 0/100 (v/v)] to yield the title compound as a solid.

1. customThe title compound is prepared analogously
2. extractionthe mixture is extracted twice with DCM (2×5 ml)
3. customthe solvent is removed under vacuo
4. customThe resulting residue is purified by flash column chromatography for three times [amino phase silica gel, eluation gradient: cyclohexane/EtOAc, 100/0 to 0/100 (v/v)]